Company profile

Ticker
BDX, BDXA, BDXB
Exchange
Website
CEO
Thomas E. Polen
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
220760120

BDX stock data

(
)

Calendar

6 Aug 20
20 Sep 20
30 Sep 20

News

Quarter (USD) Jun 20 Mar 20 Dec 19 Jun 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Sep 19 Sep 18 Sep 17 Sep 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
1 Sep 20 Thomas J Spoerel Common Stock Payment of exercise Dispose F No 0 59 0 976
13 Aug 20 Jones Christopher Ian Montague Rights to Common Stock Under 1996 Directors Deferral Plan Common Stock Grant Aquire A No 261.5 57 14.91K 7,328
13 Aug 20 Scott Bertram L Rights to Common Stock Under 1996 Directors Deferral Plan Common Stock Grant Aquire A No 261.5 57 14.91K 15,619
14 Jul 20 Kaltenbach Patrick Rights to Common Stock Under BD Deferred Compensation Plan Common Stock Grant Aquire A No 263.4 620 163.31K 620
9 Jul 20 Kaltenbach Patrick Common Stock Sell Dispose S Yes 260 1,272 330.72K 10,340
82.7% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1382 1380 +0.1%
Opened positions 114 109 +4.6%
Closed positions 112 171 -34.5%
Increased positions 553 522 +5.9%
Reduced positions 505 545 -7.3%
13F shares
Current Prev Q Change
Total value 57.36B 52.48B +9.3%
Total shares 239.63M 228.53M +4.9%
Total puts 1.21M 1.42M -14.7%
Total calls 782.73K 1.01M -22.4%
Total put/call ratio 1.5 1.4 +10.0%
Largest owners
Shares Value Change
Vanguard 25.1M $6.01B +4.4%
N Price T Rowe Associates 22.06M $5.28B +0.5%
BLK BlackRock 20.76M $4.97B +9.2%
FMR 12.36M $2.96B +35.7%
STT State Street 12.2M $2.92B +6.2%
Wellington Management 8.96M $2.14B +5.7%
MS Morgan Stanley 7.2M $1.72B +22.0%
Massachusetts Financial Services 4.24M $1.02B +3.9%
Geode Capital Management 4.11M $981.6M +9.7%
FSZ Fiera Capital 3.84M $919.58M +6.3%
Largest transactions
Shares Bought/sold Change
FMR 12.36M +3.25M +35.7%
BLK BlackRock 20.76M +1.76M +9.2%
MS Morgan Stanley 7.2M +1.3M +22.0%
American Century Companies 2.42M +1.17M +94.3%
Citadel Advisors 1.11M +1.11M NEW
Vanguard 25.1M +1.06M +4.4%
MKFCF Mackenzie Financial 1.69M -963.17K -36.3%
Generation Investment Management 2.58M +866.02K +50.5%
STT State Street 12.2M +707.7K +6.2%
Flossbach Von Storch 2.51M +638.93K +34.1%

Financial report summary

?
Management Discussion
  • (a)The presentation of prior-period amounts reflects the reclassification of $3 million associated with the movement, effective on October 1, 2019, of certain products from the Medication Delivery Solutions unit to the Medication Management Solutions unit.
  • Third quarter Medical segment revenues reflected declines in the Medication Delivery Solutions and Diabetes Care units that were partially offset by growth in the Medication Management Solutions and Pharmaceutical Systems units. The Medication Delivery Solutions unit's third quarter revenues reflected an unfavorable impact relating to the COVID-19 pandemic due to declines in non-COVID-19 procedures which require general medical devices, particularly in the United States and China. As expected, the Medication Delivery Solutions unit's third quarter revenues in China were also unfavorably impacted by a new volume-based procurement process which has been adopted by several of China's provinces. Growth driven by pandemic-related infusion pump orders in the Medication Management Solutions unit was partially offset by the delay of other shipments of AlarisTM infusion pumps in the United States, as previously discussed above. Third quarter revenues in the Diabetes Care unit primarily reflected a pandemic-related shift of U.S. orders to the second quarter of fiscal year 2020, which resulted in a lower level of orders in the third quarter. The Pharmaceutical Systems unit's reflected continued strength in demand for prefillable products.
  • Medical segment income for the three and nine-month periods is provided below.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: accrual, AG, Aircraft, antigen, campaign, category, Certificate, certification, Citibank, Computershare, consumption, Deposit, depositary, immunoassay, imposition, lab, launch, monthly, nasal, overhead, ownership, persist, plant, Polen, portable, procedure, prospective, quarterly, Receipt, registered, Registrar, reopen, repaid, repayment, responding, resurgence, retail, Secretary, sequential, shift, simple, stay, Straub, swab, unpredictable, vaccination, VeritorTM
Removed: balloon, initial, project